Analysts covering EyePoint have refreshed their models, with bullish price targets now clustered in the US$29 to US$35 range. These revisions are being linked to more detailed valuation work on the ...
Executives from 4D Molecular Therapeutics (NASDAQ:FDMT) outlined the company’s gene therapy platform, clinical progress, and ...
The StateWide Fraud of the Month is a component of the Senior Medicare Patrol (SMP), the definitive resource for New York State's older adults and caregivers to detect, prevent, and report healthcare ...
– Active Phase 3 programs for DURAVYU in wet AMD and DME, the two largest multi-billion-dollar retinal disease markets – – Topline data for DURAVYU in DME anticipated in 2H 2027 – WATERTOWN, Mass., ...
- Active Phase 3 programs for DURAVYU in wet AMD and DME, the two largest multi-billion-dollar retinal disease markets - WATERTOWN, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: ...
The Trump administration’s provisional ban on Medicare enrollment of equipment suppliers, aimed at cracking down on fraud, ...
WATERTOWN, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with ...
Good morning. My name is Michelle, and I'll be your conference operator today. At this time, I would like to welcome everyone to the EyePoint Fourth Quarter 2025 Financial Results and Recent Corporate ...
The government plans a six-month moratorium on supplier enrollment in the Medicare program to find ways to stop what it called “longstanding instances of fraud, waste, and abuse” by certain companies.
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2025 Earnings Call Transcript March 4, 2026 EyePoint Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.81426 EPS, expectations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results